Physician profile
Mark W Shen
NPI 1265401285
$8,857.19
in general payments reported to CMS, 2019-2025
57 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,202 · 2020: $700 · 2021: $389 · 2022: $1,550 · 2023: $1,458 · 2024: $1,274 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.83 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,491.29 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $633.79 | 2019-2025 | Farxiga, Breztri, Flumist Quadrivalent |
| Lilly USA, LLC | $622.08 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Abbott Laboratories | $608.88 | 2021-2025 | Freestyle Libre, Ensite Precision, Proclaim |
| Novo Nordisk INC | $584.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.62 | 2019-2025 | Jardiance |
| Pfizer INC. | $377.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $297.18 | 2019-2025 | Shingrix, Arexvy, Pediarix |
| Novartis Pharmaceuticals Corporation | $289.40 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $243.08 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $235.90 | 2019-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $226.02 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $175.83 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $161.36 | 2022-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $154.08 | 2019-2020 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.